The ARHGEF28 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the ARHGEF28 gene in the human HT29 colorectal adenocarcinoma cell line. This loss-of-function model enables investigation of ARHGEF28-dependent signaling and its roles in epithelial cell biology. The polyclonal format captures a diverse spectrum of gene-disrupted alleles within the population, offering a robust system for studying gene function without the clonal selection bias inherent to single-cell-derived lines. The cells are supplied as a ready-to-use resource for downstream experimental applications.
The HT29 cell line was originally established from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. These adherent, epithelial-like cells are widely employed as a model for intestinal epithelial biology and colorectal cancer research. HT29 cells retain key features of the colonic epithelium, including the ability to form polarized monolayers and tight junctions, making them suitable for studying barrier function, cell adhesion, and transepithelial transport. Their genetic background and signaling network provide a relevant context for exploring oncogenic processes and epithelial homeostasis.
ARHGEF28 encodes a Rho guanine nucleotide exchange factor that specifically activates Rho GTPases, predominantly RhoA, by catalyzing GDP/GTP exchange. In response to upstream signals such as integrin engagement, Src kinases, receptor tyrosine kinases, and G protein-coupled receptors, ARHGEF28 promotes RhoA-mediated downstream signaling. Key effectors include ROCK, which phosphorylates myosin light chain (MLC) and LIM kinase (LIMK), leading to cofilin inactivation and actin stress fiber stabilization. ARHGEF28 interacts with focal adhesion components paxillin and FAK, as well as ??-catenin, IKK??, and microtubules, linking RhoA activity to SRF/MRTF-mediated gene transcription. Through these interactions, ARHGEF28 coordinates actin cytoskeleton dynamics, focal adhesion maturation, and transcriptional programs governing cell migration and proliferation.
In the context of HT29 colorectal adenocarcinoma cells, disruption of ARHGEF28 expression offers a valuable tool to dissect its contribution to malignant phenotypes. Given the established roles of RhoA signaling in cancer cell invasion, metastasis, and cytoskeletal reorganization, this knockout model is particularly relevant for colorectal cancer progression studies. Furthermore, since HT29 cells can form functional epithelial barriers, ARHGEF28 knockout cells allow interrogation of the gene??s impact on intestinal epithelial barrier integrity and tight junction regulation??processes often dysregulated in inflammatory bowel disease and cancer. The model thus bridges basic signaling mechanisms and translational research in gastrointestinal oncology.
Researchers can employ this polyclonal knockout population in various experimental workflows. Western blotting and RT-qPCR confirm ARHGEF28 depletion, while RhoA activation assays (G-LISA) and phospho-MLC analysis assess signaling output. Immunofluorescence visualizes stress fibers and focal adhesions, complementing migration/invasion assays and cell adhesion studies. Barrier integrity can be evaluated by TEER measurements. Co-immunoprecipitation maps protein interactions. These applications support drug target screening for anti-metastatic therapies, Rho pathway analysis, and intestinal epithelial research. For further details, please contact Ascent Research.
